PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 18, 2026International Journal of Surgery0 citationsOpen Access

Human acellular dermal matrix for middle hepatic vein reconstruction in living donor liver transplantation: a prospective feasibility and safety study

View Full Paper
GCGwang-Sik ChunMYMin‐Kyung YeoSKSeok-Hwan Kim

Key Points

  • The study aims to evaluate the feasibility and safety of human acellular dermal matrix (ADM) in reconstructing the middle hepatic vein (MHV) during living donor liver transplantation.
  • Conducted a prospective single-center cohort study with adults undergoing LDLT using ADM.
  • Compared outcomes against historical controls utilizing Hemashield and PTFE.
  • Assessed primary endpoints of early-phase patency and major structural complications.
  • Performed independent radiologist evaluations using Doppler ultrasonography and computed tomography.
  • Used Kaplan–Meier estimates and log-rank tests for patency comparisons.
  • ADM achieved 95.0% patency at 3 months and 85.0% at 6 months.
  • At 18 months, patency rates were 62.5% for ADM compared to 50.0% for PTFE and 47.5% for Hemashield.
  • No ADM grafts required re-intervention, with no infections or duodenal invasions recorded.
  • Some ADM occlusions correlated with large bilomas, suggesting secondary infection as a potential cause.

Abstract

Background: During living donor liver transplantation (LDLT), middle hepatic vein (MHV) reconstruction requires a conduit that preserves early venous outflow while avoiding late device-related complications typical of synthetic grafts. We evaluated human acellular dermal matrix (ADM) as an off-the-shelf biological conduit. Methods: In a prospective single-center cohort (2022–2025), adults undergoing LDLT with MHV reconstruction using ADM ( n = 40) were followed. Outcomes were benchmarked against historical controls using Hemashield ( n = 40) or polytetrafluoroethylene (PTFE; n = 20). Primary endpoints were early-phase patency (≤6 months) and major structural complications. Two blinded radiologists independently reviewed serial Doppler ultrasonography and contrast-enhanced computed tomography with consensus adjudication. Patency was estimated by Kaplan–Meier and compared with the log-rank test. Results: ADM achieved excellent early patency 95.0% (83.5–98.6) at 3 months; 85.0% (70.9–92.9) at 6 months. At 18 months, patency was 62.5% for ADM versus 50.0% (PTFE) and 47.5% (Hemashield) (log-rank P = 0.785). No ADM graft required re-intervention, and no graft infection or duodenal invasion occurred (0/40 vs 2/60 3.3% in synthetic cohorts). Baseline characteristics were comparable. Case review showed that several ADM occlusions were associated with large bilomas, where secondary infection rather than intrinsic graft failure likely triggered thrombosis. Conclusions: ADM is a feasible and safe biological conduit for MHV reconstruction, delivering robust patency throughout the critical period of graft regeneration while avoiding catastrophic complications observed with synthetic materials. These hypothesis-generating results support a randomized trial and introduce the concept of ADM as a temporary biological scaffold. Given its excellent early patency and safety profile, ADM should be considered a valuable addition to the surgical armamentarium with potential to redefine success in venous reconstruction.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Chun et al. (2026) studied this question.

synapsesocial.com/papers/69e3209340886becb653f9d0https://doi.org/10.1097/js9.0000000000005143
Ask AI
Helpful
Bookmark
Share
View Full Paper